Biotech Jonathan Wosen STAT Plus: FDA’s Califf says congressional report on Aduhelm controversy contained ‘no surprises’
Biotech Adam Feuerstein STAT Plus: New Biogen CEO: New drug launches, more cost cuts, but no ‘radical left turns’ needed
Biotech Matthew Herper STAT Plus: BioMarin executives express confidence around hemophilia gene therapy
Business Bob Herman and Tara Bannow STAT Plus: The health care providers and insurers we’re watching at JPM23 — and why
Biotech Adam Feuerstein and Allison DeAngelis STAT Plus: Money troubles and M&A: What’s on biotech insiders’ minds ahead of a not-so-celebratory JPM week
Biotech Jonathan Wosen STAT Plus: Invitae’s new CEO on why the genetic testing firm stopped chasing ‘volume at all costs’
Biotech Allison DeAngelis STAT Plus: Biotech startups are hungry for dollars. Here’s what one pharma executive was looking for at JPM
Insurance Tara Bannow STAT Plus: Insurers hint at suing Biden administration over plans for Medicare Advantage audits
Biotech Jason Mast STAT Plus: Still hoping for looser FDA rules, Regeneron says it will test durable antibody for Covid
Hospitals Tara Bannow STAT Plus: Medicare Advantage-focused Oak Street, Agilon Health chart out growth at J.P. Morgan
Biotech Jonathan Wosen and Allison DeAngelis STAT Plus: A flurry of pharma acquisitions kick off JPM week after a slow year for deals